Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Biologicals (Print)

• Publication date

  2002-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1006/BIOL.2002.0334PMID 12127317
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Determination of adequate moisture content for efficient dry-heat viral inactivation in lyophilized factor VIII by loss on drying and by near infrared spectroscopy.

  1998cited by this paper
• Inactivation of Lipid‐Enveloped Viruses in Proteins by Caprylate

  1991cited by this paper
• Inactivation of Lipid‐Enveloped Viruses in Labile Blood Derivatives by Unsaturated Fatty Acids

  1988cited by this paper
• Inactivation of viruses in labile blood derivatives. I. Disruption of lipid‐enveloped viruses by tri(n‐butyl)phosphate detergent combinations

  1985cited by this paper
• Preparation of human immunoglobulin by caprylic acid precipitation.

  1984cited by this paper
• Stabilization of Human Albumin by Caprylate and Acetyltryptophanate

  1984cited by this paper
• The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and beta1-lipoprotein into subfractions of human plasma.

  1949cited by this paper
• CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. XXXVI. INACTIVATION OF THE VIRUS OF HOMOLOGOUS SERUM HEPATITIS IN SOLUTIONS OF NORMAL HUMAN SERUM ALBUMIN BY MEANS OF HEAT.

  1948cited by this paper
• Preparation and properties of serum and plasma proteins; a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids.

  1946cited by this paper
• Preparation and properties of serum and plasma proteins; a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids.

  1946cited by this paper

• Octanoic acid addition: a simple, affordable modification that overcomes lipid removal limitations of traditional antivenom production processes.

  2025cites this paper
• Validation of adventitious agent safety in Yimmugo®, a novel IVIG preparation for human use

  2025cites this paper
• Advances in the Pharmaceutical Development of Antibody-Oligonucleotide Conjugates.

  2025cites this paper
• Viral clearance capability of monoclonal antibody purification.

  2024cites this paper
• Unraveling How Antimicrobial Lipid Mixtures Disrupt Virus-Mimicking Lipid Vesicles: A QCM-D Study

  2024cites this paper
• Antibody-Drug Conjugate Overview: a State-of-the-art Manufacturing Process and Control Strategy

  2024cites this paper
• Modeling virus filtration: Materials, applications, and mechanism

  2024cites this paper
• Application of a Caprylate/Chromatography Purification Process for Production of a Hepatitis B Immune Globulin from Pooled Human Plasma

  2023cites this paper
• Complexes of an Anionic Surfactant with Chitosan and Its Hydrophobic Derivatives As Disinfectants against SARS-CoV-2

  2023cites this paper
• APPLICATION OF FORMULATION PRINCIPLES TO STABILITY ISSUES ENCOUNTERED DURING PROCESSING, MANUFACTURING, AND STORAGE OF DRUG SUBSTANCE AND DRUG PRODUCT PROTEIN THERAPEUTICS.

  2023cites this paper
• UV-LED irradiation reduces the infectivity of herpes simplex virus type 1 by targeting different viral components depending on the peak wavelength.

  2022cites this paper
• MCR-Raman spectroscopy of sodium octanoate micelles in aqueous solutions

  2022cites this paper
• Caprylate/chromatography process to produce highly purified tetanus immune globulin from human plasma

  2022cites this paper
• Application of a caprylate/chromatography purification process for production of a high potency rabies immune globulin from pooled human plasma.

  2021cites this paper
• The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19

  2021cites this paper
• Nanofiltration as a robust method contributing to viral safety of plasma‐derived therapeutics: 20 yearsʼ experience of the plasma protein manufacturers

  2020cites this paper
• Convalescent Plasma Therapy for COVID-19: State of the Art

  2020cites this paper
• The Role of Nanofiltration in the Pathogen Safety of Biologicals: An Update

  2020cites this paper
• Laser diagnostics of self-organization of amphiphiles in aqueous solutions on the example of sodium octanoate

  2020cites this paper
• Membrane and Virus Filter Trends in the Processes of Biopharmaceutical Production

  2020cites this paper
• Evaluation of the effectiveness of the SurePure Turbulator ultraviolet-C irradiation equipment on inactivation of different enveloped and non-enveloped viruses inoculated in commercially collected liquid animal plasma

  2019cites this paper
• Exo-Metabolites of Phaseolus vulgaris-Nodulating Rhizobial Strains

  2019cites this paper
• The application of caprylic acid in downstream processing of monoclonal antibodies.

  2019cites this paper
• An overview of plasma fractionation

  2018cites this paper
• What can be learned in the snake antivenom field from the developments in human plasma derived products?

  2018cites this paper
• Multiple functions of caprylic acid-induced impurity precipitation for process intensification in monoclonal antibody purification.

  2018cites this paper
• A review and novel classification of Bunyavirales

  2018cites this paper
• Biological Safety of a Highly Purified 10% Liquid Intravenous Immunoglobulin Preparation from Human Plasma

  2017cites this paper
• Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid

  2017cites this paper
• Current status and new developments in the production of plasma derivatives

  2016cites this paper
• Principles of Treatment of Primary Immunodeficiencies

  2016cites this paper
• Anti-Human Platelet Antigen-1a Immunoglobulin G Preparation Intended to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia

  2016cites this paper
• The Production Processes and Biological Effects of Intravenous Immunoglobulin

  2016cites this paper
• Minipool Caprylic Acid Fractionation of Plasma Using Disposable Equipment: A Practical Method to Enhance Immunoglobulin Supply in Developing Countries

  2015cites this paper
• Caprylic acid‐induced impurity precipitation from protein A capture column elution pool to enable a two‐chromatography‐step process for monoclonal antibody purification

  2015influential citation
• Utilisation de la précipitation d'acide caprylique pour la purification de protéines

  2015cites this paper
• Session 1.5: Other Viral Clearance and Inactivation Approaches (Multimodal Chromatography, Membrane Chromatography, Chemical Precipitation)

  2015cites this paper
• Industrial application of impurity flocculation to streamline antibody purification processes

  2015cites this paper
• Chromatin-mediated depression of fractionation performance on electronegative multimodal chromatography media, its prevention, and ramifications for purification of immunoglobulin G.

  2014cites this paper
• A new intravenous immunoglobulin (BIVIGAM®) for primary humoral immunodeficiency

  2014cites this paper
• Immunoglobulin Replacement Therapy: A Twenty-Year Review and Current Update

  2014cites this paper
• Ebola virus convalescent blood products: Where we are now and where we may need to go

  2014cites this paper
• Robustness of nanofiltration for increasing the viral safety margin of biological products.

  2014cites this paper
• Emerging Unit Operations (Session III): Hydroxyapatite, Mixed-Mode, and Adsorptive Membrane Chromatography; UV-C Inactivation; Chemical Precipitation

  2014cites this paper
• need to go

  2014cites this paper
• Safety of snake antivenom immunoglobulins: Efficacy of viral inactivation in a complete downstream process

  2013cites this paper
• Caprylic acid precipitation method for impurity reduction: An alternative to conventional chromatography for monoclonal antibody purification

  2012cites this paper
• Ensuring the Biologic Safety of Plasma-Derived Therapeutic Proteins

  2012cites this paper
• Studies on the fractionation of equine antivenom IgG by combinations of ammonium sulfate and caprylic acid.

  2012cites this paper
• Low pH formulation of whole IgG antivenom: impact on quality, safety, neutralizing potency and viral inactivation.

  2012cites this paper
• Ensuring Virus Safety of Plasma Products

  2012cites this paper
• Purification of IgG and albumin from human plasma by aqueous two phase system fractionation

  2012cites this paper
• Plasma fractionation

  2012cites this paper
• Avian influenza virus inactivation by caprylic acid, sodium caprylate, and monocaprylin

  2011cites this paper
• Efficacy, Pharmacokinetics, Safety, and Tolerability of Flebogamma® 10% DIF, a High-Purity Human Intravenous Immunoglobulin, in Primary Immunodeficiency

  2010cites this paper
• Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance

  2010cites this paper
• The use of native cation‐exchange chromatography to study aggregation and phase separation of monoclonal antibodies

  2010cites this paper
• [Guidelines for the production, control and regulation of snake antivenom immunoglobulins].

  2010cites this paper
• Recovery and purification process development for monoclonal antibody production

  2010cites this paper
• Investigations of prion and virus safety of a new liquid IVIG product.

  2008cites this paper
• Intravenous Immunoglobulins: Evolution of Commercial IVIG Preparations

  2008cites this paper
• Plasma-derived biological medicines used to promote haemostasis

  2008cites this paper
• Clearance of dengue virus in the plasma‐derived therapeutic proteins

  2008cites this paper
• Characterization of the inhibition of enveloped virus infectivity by the cationic acrylate polymer eudragit E100.

  2007cites this paper
• Assessment of viral inactivation during pH 3.3 pepsin digestion and caprylic acid treatment of antivenoms.

  2007cites this paper
• Modern Plasma Fractionation

  2007cites this paper
• [Plasma fractionation in the world: current status].

  2007cites this paper
• Chapter 22 – IVIG and Derivatives

  2007cites this paper
• Fractionnement plasmatique international : etat des lieux Plasma fractionation in the world: Current status

  2007cites this paper
• Partitioning and inactivation of viruses by the caprylic acid precipitation followed by a terminal pasteurization in the manufacturing process of horse immunoglobulins.

  2007cites this paper
• Fractionnement plasmatique international : état des lieux

  2007cites this paper
• Safety and tolerability of a novel chromatography‐based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura

  2007cites this paper
• Adverse reactions and pathogen safety of intravenous immunoglobulin.

  2007cites this paper
• A new liquid, intravenous immunoglobulin product (IGIV 10%) highly purified by a state‐of‐the‐art process

  2007cites this paper
• Evaluation of viral clearance in the production of HPV-16 L1 virus-like particles purified from insect cell cultures.

  2006cites this paper
• Differences between IGIV products: impact on clinical outcome.

  2006cites this paper
• Comparative study of the anti-inflammatory effect of two intravenous immunoglobulin preparations manufactured by different processes.

  2006cites this paper
• Purification of intravenous immunoglobulin G from human plasma – aspects of yield and virus safety

  2006cites this paper
• The use of rabbit polyclonal antibodies to assess neoantigenicity following viral reduction of an alpha-1-proteinase inhibitor preparation.

  2006cites this paper
• A modified caprylic acid method for manufacturing immunoglobulin G from human plasma with high yield and efficient virus clearance

  2006cites this paper
• Products for clotting factor replacement in developing countries.

  2005cites this paper
• Products for Clotting Factor Replacement in Developing Countries

  2005cites this paper
• Cost savings from intravenous immunoglobulin manufactured from chromotography/caprylate (IGIV-C) in persons with primary humoral immunodeficiency disorder.

  2005cites this paper
• Critical Decisions in Selecting an Intravenous Immunoglobulin Product

  2005cites this paper
• Immunoglobulin Replacement Therapy in Primary Antibody Deficiency Diseases – Maximizing Success

  2005cites this paper
• Virus safety of intravenous immunoglobulin

  2005cites this paper
• Assessment of the viral safety of antivenoms fractionated from equine plasma

  2004cites this paper
• Table 2 : Guidelines for Managing Patients with Antibody Deficiency

  2004cites this paper
• IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life

  2004cites this paper
• Strengths and limitations of the model virus concept.

  2004cites this paper
• Virus inactivation in the 1990s -and into the 21st century. Part 6, inactivation methods grouped by virus

  2003cites this paper
• A randomized double-blind trial

  2003cites this paper
• Hepatitis C Virus Infection: Detection and Treatment

  2003cites this paper
• Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process

  2003cites this paper
• Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial.

  2003cites this paper
• Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV‐C, 10% (Gamunex™, 10%)

  2003cites this paper
• Transfusion–Transmitted Viruses

  2003cites this paper
• Properties of a new intravenous immunoglobulin (IGIV‐C, 10%) produced by virus inactivation with caprylate and column chromatography

  2003cites this paper
• Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%).

  2003cites this paper
• Part 6, Inactivation Methods Grouped by Virus

  2003cites this paper